Rapid screening and speed of scale-up in protein therapeutics are critical factors in today’s immuno-oncology workflow. The ability to swiftly develop novel therapies often depends on cost-effective candidate screening enabled by technology innovations and process improvements that optimize and expedite the journey from original idea to commercial-scale production.

Learn about Thermo Fisher Scientific’s unique approach to speeding up development timelines by starting with gene optimization and transient protein expression and purification pilots. Additionally, explore the integrated workflow to rapidly move from R&D and pre-clinical pilots to first-in-human (FIH) trials.

Learning objectives:

1. Understand how beginning your protein project with gene synthesis can significantly expedite your path from discovery to scale-up and commercialization.

2. Identify a protein-independent workflow to obtain high expression yields and titers in biologics development from early stage target-to-lead all the way through to commercial production

3. Learn new strategies to accelerate timelines without introducing risks that may jeopardize IND filing and delay time to clinic